| A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting (NCT05452941) | Pfizer | 2022-10-27 |
| Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045. (NCT05560555) | Pfizer | 2022-10-24 |
| Real-World Study of Ceftazidime Avibactam in China (NCT05487586) | Pfizer | 2022-10-20 |
| A Study to Learn About Recifercept in Patients With Achondroplasia (NCT05659719) | Pfizer | 2022-10-19 |
| A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir (NCT05567952) | Pfizer | 2022-10-19 |
| Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use (NCT05509400) | Pfizer | 2022-10-18 |
| A Study to Learn About Study Medicine Called PF-07261271 in Healthy People (NCT05536440) | Pfizer | 2022-10-17 |
| A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants (NCT05654181) | Pfizer | 2022-10-17 |
| A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People (NCT05580003) | Pfizer | 2022-10-17 |
| Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study). (NCT05534789) | Pfizer | 2022-10-15 |
| A Real-life Study to Learn About the Use and Effects of the CDK4/6 Inhibitors in Canadian Patients With Breast Cancer. (NCT05770713) | Pfizer | 2022-10-12 |
| A Study to Learn About the Study Medicine Called CTB+AVP in Healthy Adult People. (NCT05554237) | Pfizer | 2022-10-07 |
| A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India (NCT05329259) | Pfizer | 2022-10-06 |
| A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma (NCT05565391) | Pfizer | 2022-10-03 |
| A Study Comparing Two Forms of Tafamidis Without Food and the Amount of Tafamidis in the Blood With Food (NCT05498701) | Pfizer | 2022-09-29 |
| Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants. (NCT05544786) | Pfizer | 2022-09-28 |
| A Study of Ponsegromab in People With Heart Failure (NCT05492500) | Pfizer | 2022-09-26 |
| A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. (NCT05375955) | Pfizer | 2022-09-26 |
| A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD (NCT05431088) | Pfizer | 2022-09-22 |
| A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan (NCT05512819) | Pfizer | 2022-09-16 |
| A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older (NCT05540522) | Pfizer | 2022-09-12 |
| A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease (NCT05487040) | Pfizer | 2022-09-07 |
| A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer (NCT05643885) | Pfizer | 2022-08-31 |
| Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants (NCT05525910) | Pfizer | 2022-08-31 |
| A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction (NCT05510245) | Pfizer | 2022-08-29 |
| A Study to Compare Two Tablet Forms of Tafamidis in Healthy Participants (NCT05482308) | Pfizer | 2022-08-29 |
| Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (NCT05520138) | Pfizer | 2022-08-29 |
| Safety and Effectiveness of Apixaban Compared to Warfarin in Patients With Non-valvular Atrial Fibrillation (a Type of Irregular Heart Rhythm) at Higher Chance of Bleeding (NCT05471505) | Pfizer | 2022-08-25 |
| A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers (NCT06137703) | Pfizer | 2022-08-24 |
| A Study to Evaluate AAV9 Neutralizing Antibody Seroconversion in Household Contacts. (NCT04543357) | Pfizer | 2022-08-17 |
| A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC) (NCT05463952) | Pfizer | 2022-08-16 |
| A Preliminary Study to Evaluate PF-07264660 in Healthy Participants (NCT05496738) | Pfizer | 2022-08-16 |
| A First-In-Human Study of the Study Medicine, Called PF-07291177, in Healthy Adult Participants (NCT05434091) | Pfizer | 2022-08-15 |
| Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age (NCT05489328) | Pfizer | 2022-08-15 |
| Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women (NCT04766086) | Pfizer | 2022-08-12 |
| Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only) (NCT05399485) | Pfizer | 2022-08-09 |
| Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only) (NCT05399459) | Pfizer | 2022-08-09 |
| Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV) (NCT06067191) | Pfizer | 2022-08-08 |
| Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy (NCT05429372) | Pfizer | 2022-08-08 |
| An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) (NCT05477524) | Pfizer | 2022-08-04 |
| A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System (NCT05438602) | Pfizer | 2022-08-03 |
| High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France (NCT05038228) | Pfizer | 2022-08-01 |
| A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction (NCT05478603) | Pfizer | 2022-08-01 |
| Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer (NCT05261490) | Pfizer | 2022-08-01 |
| A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India (NCT05375929) | Pfizer | 2022-07-16 |
| Korean Regulatory Post Marketing Surveillance for Somavert (NCT05131100) | Pfizer | 2022-07-13 |
| A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (NCT05217446) | Pfizer | 2022-07-11 |
| Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies (NCT05226871) | Pfizer | 2022-07-07 |
| The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials (NCT05203172) | Pfizer | 2022-07-05 |
| A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (NCT05355701) | Pfizer | 2022-07-05 |
| Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea (NCT04446039) | Pfizer | 2022-07-04 |
| A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations (NCT05446142) | Pfizer | 2022-07-01 |
| Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data (NCT05438888) | Pfizer | 2022-07-01 |
| Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002) (NCT05382364) | Pfizer | 2022-06-29 |
| Voxelotor Neurocognitive Function Study (NCT05228834) | Pfizer | 2022-06-24 |
| Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13 (NCT05408429) | Pfizer | 2022-06-24 |
| A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19 (NCT05386472) | Pfizer | 2022-06-22 |
| A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC). (NCT05858749) | Pfizer | 2022-06-20 |
| A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults (NCT05349864) | Pfizer | 2022-06-17 |
| A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants (NCT05431153) | Pfizer | 2022-06-10 |
| A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People (NCT05411588) | Pfizer | 2022-06-09 |
| This Study is to Describe and Evaluate Patients in Finland Treated With Tofacitinib for the Treatment of Ulcerative Colitis Using Real World Data. (NCT05082428) | Pfizer | 2022-05-30 |
| Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC (NCT05505175) | Pfizer | 2022-05-30 |
| Resolution of Sickle Cell Leg Ulcers With Voxelotor (NCT05561140) | Pfizer | 2022-05-30 |
| A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants (NCT05371652) | Pfizer | 2022-05-19 |
| A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis (NCT05250115) | Pfizer | 2022-05-10 |
| A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland. (NCT05363072) | Pfizer | 2022-05-02 |
| A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction (NCT05224609) | Pfizer | 2022-04-28 |
| A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (NCT05227001) | Pfizer | 2022-04-28 |
| Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan (NCT05399329) | Pfizer | 2022-04-20 |
| A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis. (NCT05387980) | Pfizer | 2022-04-19 |
| Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age (NCT05301322) | Pfizer | 2022-04-13 |
| A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19 (NCT05263908) | Pfizer | 2022-03-31 |
| A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803 (NCT05286281) | Pfizer | 2022-03-31 |
| A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease (NCT05348915) | Pfizer | 2022-03-29 |
| Generate Real World Data On Tofacitinib Induction Therapy and Changes In Clinical and Patient Reported Outcomes. (NCT05069259) | Pfizer | 2022-03-28 |
| Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (NCT05317416) | Pfizer | 2022-03-25 |
| PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) (NCT05259397) | Pfizer | 2022-03-24 |
| Korea Comirnaty Post-marketing Surveillance (NCT05032976) | Pfizer | 2022-03-18 |
| Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention (NCT05207865) | Pfizer | 2022-03-15 |
| A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors (NCT05262400) | Pfizer | 2022-03-14 |
| A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants. (NCT05339334) | Pfizer | 2022-03-10 |
| Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants (NCT05263921) | Pfizer | 2022-03-10 |
| EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease (NCT05261139) | Pfizer | 2022-03-07 |
| Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation (NCT05263895) | Pfizer | 2022-03-03 |
| Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects (NCT05156398) | Pfizer | 2022-02-28 |
| A Study to Learn About The Study Medicine (Called PF-06823859) in Healthy Chinese Participants (NCT05257798) | Pfizer | 2022-02-28 |
| Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants. (NCT05178654) | Pfizer | 2022-02-22 |
| Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis (NCT05248997) | Pfizer | 2022-02-17 |
| Pharmacokinetic Comparability Study in Healthy Participants - PF-06881894 On-Body Injector Relative to Prefilled Syringe (NCT05194579) | Pfizer | 2022-02-10 |
| A Study to Learn About Sickle Cell Disease In Adult Patients (NCT05407805) | Pfizer | 2022-02-10 |
| A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955 (NCT05206604) | Pfizer | 2022-02-09 |
| European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies (NCT05043506) | Pfizer | 2022-02-08 |
| Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD (NCT04930445) | Pfizer | 2022-02-04 |
| Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia (NCT05070845) | Pfizer | 2022-02-02 |
| A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in Denmark (NCT05452798) | Pfizer | 2022-02-01 |
| A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza (NCT05160636) | Pfizer | 2022-01-31 |
| Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib Capsule (NCT05032690) | Pfizer | 2022-01-19 |
| Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US (NCT05260684) | Pfizer | 2022-01-17 |
| Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years (NCT04821310) | Pfizer | 2022-01-13 |